RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2025 10-K Annual Report
RHYTHM PHARMACEUTICALS, INC. (RYTM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
RHYTHM PHARMACEUTICALS, INC. FY2025 10-K Analysis
Business Overview
- • Core business: Development and commercialization of MC4R agonist therapies to treat rare neuroendocrine diseases causing severe obesity and hyperphagia
- • New product focus: Anticipated 2026 US launch of IMCIVREE for acquired hypothalamic obesity, plus Phase 3 trial initiation for oral MC4R agonist bivamelagon
Management Discussion & Analysis
- • Revenue $422.5M to date from IMCIVREE product sales; commercial launch in US Q1 2021, France March 2022, ongoing growth expected
- • Net loss $196.5M in 2025 vs $260.6M in 2024; operating expenses increased with R&D down to $167.3M from $238M, SG&A up to $194.9M from $144.3M
Risk Factors
- • Regulatory risk from FDA, EC, MHRA approvals for setmelanotide expansion delays or denials impacting U.S., Canada, EU, UK launch
- • Geopolitical risk due to European operations and recent acquisition of Netherlands-based Xinvento B.V., with CHI program still in discovery phase
RHYTHM PHARMACEUTICALS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$190M
▲ +45.8% YoY
Net Income
-$197M
▲ +24.6% YoY
Operating Margin
-101.2%
▲ +10284bp YoY
Net Margin
-103.6%
▲ +9669bp YoY
ROE
-141.3%
▲ +105800bp YoY
Total Assets
$480M
▲ +22.4% YoY
EPS (Diluted)
$-3.11
▲ +28.3% YoY
Operating Cash Flow
-$116M
▼ -1.6% YoY
Source: XBRL data from RHYTHM PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on RHYTHM PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.